Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

Analysis of the Immunogenetic Profile of Patients With Aggressive Course of Malignant Neoplastic Process Resistant to the Standard Treatment Approaches: a Translational Study

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour tissue, and and cancer testis antigenes expression on tumour cells, as well as clinical data on patient's stage, therapy, response and demographics. Possible prognostic and predictive dynamic biomarkers will be discovered for individualisation of treatment strategies

Who May Be Eligible (Plain English)

Who May Qualify: - Signed inform consent - Histolgically verified solid tumour - Receiving systemic therapy for neoplasm - Has archival tumour tissue - Provide biosamples with living tumour tissue or blood samples for immunologic assessment Who Should NOT Join This Trial: - Concurrent Lymphoprolipherative disorder - Patients after stem cell or bone marrow thansplantation - Incomplete informaton on previous cancer history or medical history - Patients with known primary weakened immune system - Patients receiving immunosupressive therapy for concurrent illness - Pregnant patients Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Signed inform consent * Histolgically verified solid tumour * Receiving systemic therapy for neoplasm * Has archival tumour tissue * Provide biosamples with living tumour tissue or blood samples for immunologic assessment Exclusion Criteria: * Concurrent Lymphoprolipherative disorder * Patients after stem cell or bone marrow thansplantation * Incomplete informaton on previous cancer history or medical history * Patients with known primary immunodeficiency * Patients receiving immunosupressive therapy for concurrent illness * Pregnant patients

Locations (1)

N.N. Petrov NMRC of Oncology, Oncoimmunology dep.
Saint Petersburg, Russia